156185-88-5

Basic information

• Product Name: 3-Amino-(2S)-phenylsulfonylaminopropionicacid
• Synonyms: 3-Amino-(2S)-phenylsulfonylaminopropionicacid;3-AMINO-(2S)-PHENYLSULPHONYLAMINO-PROPIONIC ACID
• CAS NO: 156185-88-5
• Molecular Formula: C₉H₁₂N₂O₄S
• Molecular Weight: 244.26758
• Mol File: 156185-88-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 465.9±55.0 °C(Predicted)
• Appearance: /
• Density: 1.422±0.06 g/cm3(Predicted)
• PKA: 2.36±0.16(Predicted)
• CAS DataBase Reference: 3-Amino-(2S)-phenylsulfonylaminopropionicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-(2S)-phenylsulfonylaminopropionicacid(156185-88-5)
• EPA Substance Registry System: 3-Amino-(2S)-phenylsulfonylaminopropionicacid(156185-88-5)

Safety Data

• Hazardous Substances Data: 156185-88-5(Hazardous Substances Data)

Upstream product

• 156185-87-4 N-phenylsulfonyl-L-asparagine 
• 98-09-9 benzenesulfonyl chloride 
• 402579-11-7 Nα-benzenesulfonyl-L-asparagine 

Downstream Products

• 156185-89-6 tert-butyl (2S)-N-benzenesulfonyl-2,3-diaminopropionate 
• 228851-06-7 (S)-3-[4-(2-Amino-ethoxy)-benzoylamino]-2-benzenesulfonylamino-propionic acid 
• 174665-30-6 3-{4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid 
• 174665-29-3 3-{4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 298692-95-2 3-[4-(2-aminopyridin-6-ylethyl)benzoylamino]-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 298692-93-0 3-{4-[2-(N-BOC-amino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 174665-87-3 2(S)-benzenesulfonylamino-3-{4-[2-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)ethyl]benzoylamino}propionic acid tert-butyl ester 
• 215050-25-2 2-benzenesulfonylamino-3-(3,4-diamino-benzoylamino)-propionic acid tert-butyl ester 
• 215050-13-8 2-benzenesulfonylamino-3-(4-fluoro-3-nitro-benzoylamino)-propionic acid tert-butyl ester 
• 215050-24-1 3-(4-amino-3-nitro-benzoylamino)-2-benzenesulfonylamino-propionic acid tert-butyl ester 
• 215050-27-4 2-benzenesulfonylamino-3-[(2-phenylamino-3H-benzoimidazole-5-carbonyl)-amino]-propionic acid tert-butyl ester 
• 215050-26-3 3-[4-amino-3-(3-phenyl-thioureido)-benzoylamino]-2-benzenesulfonylamino-propionic acid tert-butyl ester 
• 215050-16-1 C₃₃H₄₇N₇O₁₁S 
• 215050-20-7 2-benzenesulfonylamino-3-{4-[4-(tert-butoxycarbonylamino-tert-butoxycarbonylimino-methyl)-piperazin-1-yl]-3-nitro-benzoylamino}-propionic acid tert-butyl ester 

Relevant articles and documents

BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS

The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.

Design, synthesis and biological evaluation of nonpeptide integrin antagonists

Recent studies demonstrated that peptide and antibody antagonists of integrin α(v)β3 block angiogenesis and tumor growth. In this article, the design, synthesis and biological evaluation of a series of nitroaryl ether-based, nonpeptide mimetics are described. The design of these compounds was based on Merck's arylether/α-aminoacid/guanidine framework and incorporates a novel nitroaryl system. The synthesized mimetics were tested against a variety of integrins (α(v)β3, α(IIb)β3, and α(v)β5) in order to determine their binding selectivity and ability to inhibit cell adhesion. Selected compounds were also tested for their ability to inhibit angiogenesis in vivo in the CAM (chick chorioallantoic membrane) assay. From the generated compound library, compounds 16 and 19 proved to be potent and selective inhibitors of α(IIb)β3 (IC50=14nM) whereas compound 11 showed excellent in vivo inhibition of angiogenesis (at 30μg/embryo). Copyright (C) 1998 Elsevier Science Ltd.

Fibrinogen receptor antagonists

Novel fibrinogen receptor antagonists of the formula: are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.